Drug Deal Disclosure Act
Sponsored By: Senator Wyden, Ron [D-OR]
Introduced
Summary
Public disclosure of most private drug pricing deals with federal offices. The bill would require rapid public release of contracts, communications, and related records, limit political or reputational reasons for hiding them, and create new oversight and budget analyses.
Show full summary
- Drug manufacturers would see named federal agreements listed publicly, including deals by AbbVie, Amgen, AstraZeneca, Eli Lilly, Pfizer, and Novo Nordisk. Records for listed agreements and any new or modified qualifying deals would have to be disclosed within 30 days and cover agreements entered on or after January 20, 2025.
- Federal offices including the Executive Office of the President, the Department of Health and Human Services, and the Department of Commerce would have to disclose agreements that trigger coverage. Triggers include price reductions tied to international reference pricing, direct-to-consumer discounts or sales, import duty changes, investment or repatriation commitments, special terms for CMS demonstration models, Strategic National Stockpile purchases, and receipt of FDA priority vouchers.
- The public and Congress would gain broader access to documents while allowing redaction for proprietary or foreign-law protected pricing. The Secretary would have to state whether they hold confidential pricing information and publish written justifications for any redactions, and the Congressional Budget Office and the Government Accountability Office would produce independent budgetary and oversight analyses.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
5 provisions identified: 4 benefits, 0 costs, 1 mixed.
Budget and oversight reports on deals
The bill would require the CBO Director and the Comptroller General to jointly publish, within 90 days after the released agreements are posted, a report on the economic and budget effects of all disclosed agreements. That report would show expected effects for each agreement, cost savings by insurance status (including uninsured people), and impacts on Medicare, Medicaid, and Exchange plans. The bill would also require HHS to send Congress, within 15 days after the release, a report listing every document released or withheld and explaining legal reasons for any redactions.
Public posting of drug deals
The bill would require the HHS Secretary to publish, in one searchable place, records tied to qualifying drug-maker agreements made on or after January 20, 2025. The Secretary would have to post those records not later than 30 days after enactment. For any new agreement after enactment or any modification that meets the rules, the Secretary would post records within 30 days after ratification. Some information could be redacted if other laws allow it.
What deals must be disclosed
The bill would list seven types of commitments that trigger disclosure for agreements made on or after January 20, 2025. Triggers include price reductions tied to foreign reference prices (including Medicare and Medicaid references), direct-to-consumer sales or discounts (including manufacturer websites or government platforms), duty or import exemptions, commitments to invest in or repatriate revenue to the U.S., special terms for Medicare innovation projects (GLOBE and GUARD), contributions or guaranteed purchases for the Strategic National Stockpile, and receipt of an FDA National Priority Review Voucher.
Published list of drug agreements
The bill would require HHS to publish records for specific agreements announced on these dates: Pfizer (Sept 30, 2025); AstraZeneca (Oct 10, 2025); EMD Serono (Oct 16, 2025); Eli Lilly and Novo Nordisk (Nov 6, 2025); Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi (all Dec 19, 2025); Johnson & Johnson (Jan 8, 2026); and AbbVie (Jan 12, 2026). The Secretary would post these records under the Act's timing rules, generally within 30 days after enactment.
Rules on redactions and withholding
The bill would prohibit withholding, delaying, or redacting records just because of reputational harm or political sensitivity. It would still allow HHS to withhold or redact proprietary pricing, pricing protected by another nation's law or court order, or other legally protected information. When HHS redacts, it would have to say whether the manufacturer provided confidential pricing and publish a written justification in the Federal Register and send that justification to Congress. These rules would take effect on enactment.
Sponsors & CoSponsors
Sponsor
Wyden, Ron [D-OR]
OR • D
Cosponsors
Peter Welch
VT • D
Sponsored 4/21/2026
Sen. Warren, Elizabeth [D-MA]
MA • D
Sponsored 4/21/2026
Sen. Gallego, Ruben [D-AZ]
AZ • D
Sponsored 4/21/2026
Sen. Merkley, Jeff [D-OR]
OR • D
Sponsored 4/21/2026
Sen. Luján, Ben Ray [D-NM]
NM • D
Sponsored 4/21/2026
Sen. Baldwin, Tammy [D-WI]
WI • D
Sponsored 4/21/2026
Sen. Whitehouse, Sheldon [D-RI]
RI • D
Sponsored 4/21/2026
Sen. Kelly, Mark [D-AZ]
AZ • D
Sponsored 4/21/2026
Sen. Sanders, Bernard [I-VT]
VT • I
Sponsored 4/21/2026
Sen. Warner, Mark R. [D-VA]
VA • D
Sponsored 4/21/2026
Sen. Smith, Tina [D-MN]
MN • D
Sponsored 4/21/2026
Sen. Hassan, Margaret Wood [D-NH]
NH • D
Sponsored 4/21/2026
Sen. Cortez Masto, Catherine [D-NV]
NV • D
Sponsored 4/21/2026
Sen. Bennet, Michael F. [D-CO]
CO • D
Sponsored 4/21/2026
Raphael Warnock
GA • D
Sponsored 4/21/2026
Sen. Hirono, Mazie K. [D-HI]
HI • D
Sponsored 4/21/2026
Sen. Cantwell, Maria [D-WA]
WA • D
Sponsored 4/21/2026
Sen. Van Hollen, Chris [D-MD]
MD • D
Sponsored 4/27/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov